This program is worth 13.0 CME credits.
Title of Program: Evidence-based Medicine Toolkit
Practice Based Learning and Improvement
System Based Practice
Interpersonal Skills and Communication
Teaching Style: Didactic, Interactive/Hands-On
Neurology Program Directors (specifically) and all Program Directors from all specialties
Neurology-related specialists and advanced practice providers
Course Director: Gary S. Gronseth, MD, FAAN
Gary S. Gronseth, MD, FAAN
Michael G. Benatar, MBChB, DPhil, MS, FAAN
Michael Glantz, MD, FAAN
David Preston, MD, FAAN
Don B. Smith, MD, FAAN
Steven R. Messe, MD, FAAN
EBM Toolkit is a 2-day, in-person training to understand and use the principles of evidence-based medicine in medical practice.
Upon completion, participants should be able to:
-Formulate a clinical question
-Perform a literature search and retrieve articles
-Obtain high quality technology assessments, reviews, and critical appraisals from national and international sources
-Determine which studies best address the clinical question
-Rate the quality of evidence
-Synthesize the evidence with clinical information
-Present this integrated information during rounds
-Demonstrate competency in/learning of ACGME Core Competencies
-Teach a full EBM training curriculum (if applicable)
-Reinforce a culture of critical analysis and synthesis of the evidence
-Integrate the core curriculum of EBM Toolkit into residency training (if applicable)
The American Academy of Neurology(AAN)/American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Evaluation (ACCME) to sponsor continuing medical education (CME) for physicians.
American Medical Association Physician Recognition Award™ The AAN/AANI designates this educational activity for a maximum of 13 credits of AMA PRA Category1 Credits™. Physicians should claim only those hours of credit that they actually spend in the educational activity.
Participants should follow instructions to take the pre-test and make preparations for the training, including reading the supporting articles for the training. Participants will attend a 2-day training from September 27-28, 2013. Following the training, participants will be required to complete a post test and submit a brief evaluation of the event to obtain CME credits.
Staff Contact Information:
Please contact Rebecca Penfold-Murray at firstname.lastname@example.org with any questions regarding this CME activity.
Participants should bring a laptop or device with a USB port. Wi-fi connection will be available for all participants. If participants do not bring a laptop, then any of the printed training materials will be furnished by the participant.
Policy on Privacy and Confidentiality:
The AAN/AANI will keep confidential and not disclose AAN member and non-member information collected through this online CME activity. The AAN/AANI has adopted and adheres to the Privacy Statement accessible at: http://www.aan.com/globals/axon/assets/3269.pdf
The AAN/AANI owns copyright in the materials used for the classroom training and online repository of resources for EBM Toolkit.
Estimated time to complete:
30 minutes: Pre Test
2 hours: Course Preparation
13+ hours (over 2 days): EBM Toolkit Training
30 minutes: Post Test
30 minutes: evaluation
Date of release: September 28, 2013
CME The AAN/AANI designates this educational activity for a maximum of 13 CME credits. Physicians should claim only those hours of credit that they actually spend in the educational activity. CME is available for one year from date of release, September 28, 2013. No CME for this program will be provided after one year unless the program is reviewed by the AAN/AANI and found current and eligible for CME.
Date of Release
Dr. Gronseth has received personal compensation for activities with Boehringer Ingleheim Pharmaceuticals Inc. as a speaker. Dr. Gronseth has received research support from American Academy of Neurology, and financial support for serving as AAN's Evidence-based Medicine Methodologist.
Dr. Benatar has received research support from CytRx Corporation.
Dr. Glantz has received personal compensation for activities with SigmaTau as a speaker and scientific advisory board member. Dr. Glantz has received research support from Exelixis Pharmaceuticals.
Dr. Preston has nothing to disclose.